Abstract: The present invention relates to a pharmaceutical composition comprising an HDAC inhibitor, a pharmaceutically acceptable acid or salt thereof or a mixture of the acid and salt, provided both in a immediate release form and in an extended release form wherein 70-90 weight % of the HDAC inhibitor is provided in the immediate release form and the remainder of the HDAC inhibitor is provided in the extended release form. In further aspects the present invention relates to a kit comprising a number of doses of an HDAC inhibitor, a pharmaceutically acceptable acid or salt thereof or a mixture of the acid and salt thereof provided both in an immediate release form and in an extended release form.

Abstract: A pharmaceutical composition comprises a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments.

Abstract: The invention relates to a pharmaceutical composition comprising a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments.